alexa What is the Best Interventional Technique for Lower Extremity Arterial Disease | OMICS International
ISSN: 2157-7420
Journal of Health & Medical Informatics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

What is the Best Interventional Technique for Lower Extremity Arterial Disease

Mallikarjuna MRE1* and Ganga V2

1Fellow in Cardiovascular Diseases, University of Arkansas for Medical Sciences, USA

2Internal Medicine, St. Vincent Health Care System, USA

*Corresponding Author:
Mallikarjuna MRE
Fellow in Cardiovascular Diseases,
University of Arkansas for Medical Sciences,
USA.
Tel: 501-686-743
E-mail: [email protected]

Received Date: August 01, 2016; Accepted Date: August 01, 2016; Published Date: August 07, 2016

Citation: Mallikarjuna MRE, Ganga V (2016) What is the Best Interventional Technique for Lower Extremity Arterial Disease. J Health Med Inform 7:e141. doi:10.4172/2157-7420.1000e141

Copyright: © 2016 Mallikarjuna MRE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Health & Medical Informatics

Editorial

The prevalence of peripheral arterial disease is between 19-30% [1]. It most commonly involves the superficial femoral artery [2]. Almost 1 in 3 patients more than 70 years of age or patients more than 50 years of age with diabetes or a history of smoking have peripheral vascular disease. However, only 50% of patients and less than 30% of physicians treating these patients are aware of this condition. The ratio of asymptomatic to symptomatic PVD is about 3:1. 30% of asymptomatic patients have total occlusions but are asymptomatic because of presence of excellent collaterals. 25% of those presenting with intermittent claudication will gradually progress over time. Most deterioration occurs in the first year after diagnosis followed by a slower progression subsequently. An ankle brachial index of less than 0.5 is an important risk factor for disease progression. The amputation rate is about 2% over 5 years. However, only 50% of those presenting with critical limb ischemia will be alive at 2 years. Thus the initial presentation is an important consideration in these patients.

The most important conservative management strategies focus on smoking cessation, control of risk factors such as diabetes, antiplatelet therapy and angiotensin receptor blockade. Supervised exercise program is a class 1 recommendation in these patients. Cilostazole also has a role in these patients. Endovascular procedures mentioned below are primarily intended in those with lifestyle limiting symptoms and those that do not respond to conservative treatment.

A number of interventional therapeutic modalities are available for use but it is difficult to compare the effectiveness of the various devices in a systematic fashion. Firstly, the nature of peripheral lesions is varied and the disease can be acute or chronic. Secondly the degree of narrowing can range from total occlusion to varying degrees of stenosis. The length of stenosis can be extremely variable from a few centimetres to several centimetres long, there can be varying degrees of calcification in the vessel and lastly the vessels involved can vary greatly in diameter. It is extremely difficult to construct a systematic study that compares the various interventional devices by controlling for all the aforementioned factors. Furthermore, the definitions of patency and restenosis and the follow up methods can be extremely variable.

Nitinol self-expanding stents are the most commonly used stents in the current day and age. However a number of factors reduce the primary patency rates of stents in peripheral vascular disease, unlike the coronary circulation where the patency rates of stents is excellent. The stents in peripheral arteries are subject to bending and torsional forces, greater lengths of stents are used in the treatment of these lesions and the flow rates in the arteries of the peripheral circulation are lower [3-5]. This has led to a disappointing primary patency rate which ranges from 45 to 90%. Covered stents have an external nitinol stent structure with a polytetrafluoroethylene liner with or without an additional heparin bioactive surface [6-8]. They are thought to prevent intimal hyperplasia and the primary patency rates are about 68% at 12 months. Several recent developments in the design of drug eluting stents have yielded primary patency rates of 84% in the treatment of lesions in the superficial femoral artery [9-11].

By eliminating metal struts the use of drug coated balloons reduces the risk of acute thrombosis [12,13]. Bailout stenting is required in 10-12% of patients often due to the dissection following balloon expansion. The use of cryoplasty balloons involves the application of cold thermal energy to the vessel wall along with the stretch produced by balloon expansion. These reduce the risk if dissection and can be used a strategy for post dilatation following stent implantation. The 12- month primary patency rates for this modality of treatment vary from 50% to 70%. As with balloon dilatation strategies mentioned above the rates of bailout stenting are between 8% and 28% [14-16].

Although a number of lesions can be either ballooned or stented a significant number of lesions do not lend themselves to such options and require additional treatment options before they can be made suitable for angioplasty. When used alone, directional atherectomy spares the vessel the trauma from stretch involved in balloon angioplasty [17,18]. However adjunctive angioplasty is needed in 60-75% of patients and bailout stenting is required in 23%. The primary patency rate of this treatment modality is about 63%. Although this rate is comparable to that obtained by balloon angioplasty it is important to note that the lesions for which rotational atherectomy is used are incredibly complex and do not allow for primary angioplasty. Atherectomy devices have the ability to aspirate atherosclerotic debris thus minimizing the risk of peripheral embolization.

Excimer laser ablates restenotic tissue and thus eliminates the risk of peripheral embolization. They also decrease the risk of platelet aggregation [19-21]. It is particularly suited for long complex calcified lesions. However adjunctive angioplasty is required in more than 60% of cases and bailout stenting is required in up to 25% of cases. In conclusion, as the lesion complexity increases a variety of treatment options are required in combination and no single treatment modality is adequate.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8198
  • [From(publication date):
    August-2016 - Feb 20, 2018]
  • Breakdown by view type
  • HTML page views : 8124
  • PDF downloads : 74
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version